Stay ahead in the rapidly evolving LNP space with the 4th LNP Formulation & Process Development Summit—the largest global meeting dedicated purely to LNPs.
Download the eBook
The official event guide is your must-have resource for exploring the latest preclinical and clinical data, tackling LNP IP challenges, and uncovering next-generation formulations for gene editing, mRNA therapeutics, cell therapies, and beyond.
With three dedicated tracks covering Analytical Development, Formulation & Delivery, and Process Development & Manufacturing, plus networking with 300+ LNP experts, this guide is your roadmap to success.
Download your copy now and accelerate your journey from concept to market.
Download the eBook
About Hanson Wade Group - 4th LNP Formulation & Process Development Summit
Successfully Fast-Track Your LNPs from Concept to Market at the Largest Meeting Dedicated Purely to LNPs Worldwide
With Arbor Biotechnologies on-track for year-end IND/CTA filing of their LNP-mediated gene editing therapy and LNPs continuing to be the hottest delivery vehicle across all payload types, completely dominating the non-viral delivery field, the promise of this delivery vehicle is truly ground-breaking!
The 4th LNP Formulation & Process Development Summit returns to Boston, as the only industry summit dedicated to unveiling the hottest pre-clinical and clinical data, overcoming the greatest challenges within the LNP IP space and uncovering the most innovative LNP formulations for extrahepatic delivery of cell therapies, gene therapies, mRNA therapeutics and beyond!
With a revamped track design, the 2025 meeting has 3 dedicated streams Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing to deep dive into an end-to-end strategy for revolutionizing the discovery and development of potent, safe and stable LNPs for a variety of applications for the patients in need.
Uniting 300+ LNP trailblazers from across the globe, this is your one-stop-shop for LNP specific networking, partnership opportunities and collaborative discussions to further fuel advancement of LNPs towards clinical development.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.